Drugs / DE-104
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00868894 | Mar 2009 → May 2010 | ocular hypertension, open-angle glaucoma | Santen Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00650338 | Mar → Sep 2008 | ocular hypertension, open-angle glaucoma | Santen Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00657579 | — | ocular hypertension, open-angle glaucoma | Santen Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00656240 | — | ocular hypertension, open-angle glaucoma | Santen Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DE-104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00656240 ↗ |
| Route | Topical | “Topical ocular application” NCT00868894 ↗ |